Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Quest For Political Capital, Legacy Could Push 'Cures' Over The Finish Line

Executive Summary

When Congress returns to work after the summer recess, the House and Senate medical innovation packages may gain momentum as legislators seek a “feather in the cap” for reelection campaigns, and House Energy and Commerce Committee Chair Fred Upton and Vice President Joe Biden look to cement legacies, say legislative analysts. Also, a Zika virus funding rider is expected be attached to a continuing resolution.


Related Content

Medical Innovation Bills On Fast Track In Congress, But Some Barriers Remain
NIH Funding Component of 21st Century Cures May Get White House Boost
Robotic Arm Inventor Says 18 Months ‘Too Long’ To Approve Novel Device
Zika Assay Reviews Are Testing The Limits Of FDA Capacity, Shuren Says
Deal To Fight Zika Virus Boosts NIH, CDC Efforts, But Offers No FDA Review Dollars
Republican Health-Care Plan Would Repeal US Device Tax
Innovation Bill Scorecard: Device, Diagnostic Provisions In Senate And House
Senate Moves To Floor Phase For Innovation Bill; Postmarket Surveillance, LDTs Could Get Attention
Senate's Medical Innovation Bill Takes Cures' Shape
'Cures' Bill Passes, As More Budget, Safety Debates Wait In The Wings